Melasma
Conditions
Brief summary
Melasma is an acquired pigmentary disorder, occurring most commonly on the face. It is more prevalent in females and darker skin types. Melasma is mainly a clinical diagnosis consisting of symmetric reticulated hypermelanosis in three predominant facial patterns: centrofacial, malar, and mandibular. Melasma, though benign, can be extremely psychologically distressing and has been shown to have a significant impact on quality of life, social and emotional wellbeing. Multiple factors are implicated in the pathogenesis of melasma; however, the definite underlying mechanisms are not yet completely established. Ultraviolet exposure is one of the leading etiological factors, besides genetic and hormonal factors.
Detailed description
Many studies examined multiple treatment options for melasma, but none of them is completely satisfactory with recurrence in most cases. Silymarin (SM) is a standardized extract from Silybum marianum seeds, is traditionally used as a hepatoprotective agent for its potent regenerative properties. Lately, SM is utilized in dermatological and cosmetic preparations for its antioxidant effect, anti-inflammatory and immunomodulatory properties. Silibinin, the main component of silymarin, has been found to have antioxidant properties. It decreases the hazardous effects of solar ultraviolet radiation and significantly prevents melanin production in a dose-dependent manner without effect on cell viability. Skin microneedling, or percutaneous collagen induction by needles, is a minimally invasive procedure that uses short fine needles to puncture the skin and stimulates fibroblast proliferation, release of growth factors and collagen production. Long-term improvement of melasma after microneedling was reported , however, the exact mechanism that promotes skin lightening is not known.
Interventions
COMBINATION_PRODUCTSilymarin
The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
PROCEDUREMicroneedling
Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
Sponsors
Assiut University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18-50 years old. * Pattern of melasma: Bilateral symmetrical facial melasma of any pattern. * Fitzpatrick skin phototypes: Types III, IV and V
Exclusion criteria
* Pregnancy and lactation. * Patients taking oral contraceptive pills, hormonal replacement therapy or treatment for chronic illness at the time of the study or during the past 6 months. * Coexistance of diseases associated with hyperpigmentation such as Addison disease. * Scarring and keloid tendency, active skin infections as active HSV. * Previous history of post inflammatory hyperpigmentation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| compare between the efficacy of topical silymarin alone and its combination with microneedling in treatment of melasma. | 3 months | Scoring of the patients according to modified Melasma Area and Severity Index (mMASI) score before and after treatment. |
Contacts
Primary ContactSahar A Ismail, Professor
Backup ContactRofaida R Shehata, PHD
Outcome results
None listed